Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-06-14
2010-10-12
Andres, Janet L (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S345000, C514S349000, C546S183000, C546S290000, C546S296000, C546S297000
Reexamination Certificate
active
07812038
ABSTRACT:
A method for the inhibition of the binding of α4β1integrin to its receptors, for example VCAM-1 (vascular cell adhesion molecule-1) and fibronectin; compounds that inhibit this binding; pharmaceutically active compositions comprising such compounds; and to the use of such compounds either a above, or in formulations for the control or prevention of diseases states in which α4β1is involved.
REFERENCES:
patent: 5182290 (1993-01-01), Albaugh
patent: 5192746 (1993-03-01), Lobl et al.
patent: 5312822 (1994-05-01), Albaugh
patent: 5451585 (1995-09-01), Albaugh
patent: 5484946 (1996-01-01), Abood et al.
patent: 5510332 (1996-04-01), Kogan et al.
patent: 5521179 (1996-05-01), Bernstein et al.
patent: 5656627 (1997-08-01), Bemis et al.
patent: 5710153 (1998-01-01), Ohmoto et al.
patent: 5721366 (1998-02-01), Abood et al.
patent: 5756466 (1998-05-01), Bemis et al.
patent: 5770573 (1998-06-01), Arrhenius et al.
patent: 5821231 (1998-10-01), Arrhenius et al.
patent: 5936065 (1999-08-01), Arrhenius et al.
patent: 6096773 (2000-08-01), Scott et al.
patent: 6194448 (2001-02-01), Biediger et al.
patent: 6972296 (2005-12-01), Biediger et al.
patent: A-92421/98 (1999-10-01), None
patent: 26 14 189 (1977-10-01), None
patent: 0 341 915 (1989-05-01), None
patent: 0 335 819 (1990-02-01), None
patent: 0355819 (1990-02-01), None
patent: 0 422 9038 (1991-04-01), None
patent: 0 508 798 (1992-10-01), None
patent: 0 512 831 (1992-11-01), None
patent: 2288800 (1995-11-01), None
patent: P0104800 (2003-12-01), None
patent: P0201729 (2005-01-01), None
patent: 7-304735 (1995-11-01), None
patent: 94045874 (1996-09-01), None
patent: WO 91/13862 (1991-09-01), None
patent: WO 9422820 (1994-10-01), None
patent: WO 95/15973 (1995-06-01), None
patent: WO 95/26958 (1995-10-01), None
patent: WO 95/32205 (1995-11-01), None
patent: WO 96/06108 (1996-02-01), None
patent: WO 98/04247 (1996-02-01), None
patent: WO 96/22966 (1996-08-01), None
patent: WO 97/43650 (1997-11-01), None
patent: WO 98/11896 (1998-03-01), None
patent: WO98/22494 (1998-05-01), None
patent: WO 99/32459 (1999-01-01), None
patent: WO 99/96434 (1999-02-01), None
patent: WO 99/10313 (1999-03-01), None
patent: WO 99/20272 (1999-04-01), None
patent: WO 99/24398 (1999-05-01), None
patent: WO 00/17197 (1999-09-01), None
patent: WO 99/52493 (1999-10-01), None
patent: WO 99/64397 (1999-12-01), None
patent: WO 00/02903 (2000-01-01), None
patent: WO 00/29019 (2000-05-01), None
patent: WO 00/47564 (2000-08-01), None
patent: WO 00/53168 (2000-09-01), None
patent: WO 00/61631 (2000-10-01), None
patent: WO 00/67746 (2000-11-01), None
patent: WO 00/68188 (2000-11-01), None
patent: WO 01/46190 (2001-06-01), None
patent: WO 98/04913 (2008-02-01), None
L. Ismaili, et al.; Synthesis of New Pyrazolo(4,3-c)quinoline-3-one Derivatives and Some Oxazolo(4,5-c)quinoline-2,4-diones; Journal of Hetercyclic Chemistry, vol. 36, No. 3, 1999, pp. 719-722; France.
J. J. Panouse, et al.; Relations structrures-activities des immunomodulateurs. Apport de la modelisation moleculaire; Annales Pharmaceutiques Francaiscs, vol. 58, No. 5, 2000, pp. 291-302.
D. Eric Walters, et al., Genetically Evolved Receptor Models: A Computational Approach to Construction of Receptor Models. J. Med. Chem., vol. 37, No. 16, 1994, pp. 2527-2536.
Andrian et al.,N England J Med348:1 (2003).
Arrhenius et al., “Small Molecule Inhibitors of the Leukocyte Integrin VLA-4”, inPeptides: Chemistry, Structure and Biology, Proceedings of the Fourteenth American Peptide Symposium, Jun. 18-23, 1995, Columbus, Ohio, UsA, pp. 337-339.
Birkofer et al.,Justus Liebigs Ann Chem628:162-170 (1959).
Crider et al.,J Pharm Sci70(2):192-195 (1981).
Flouzat et al.,Tetrahedron Lett33(32):4571-4574 (1992).
Greene et al., In “Protective Groups in Organic Synthesis”, John Willey & Sons, p. 271.
Johnson et al.,J Amer Chem Soc58:299-301 (1936).
MacLeod et al.,J Med Chem38(2)2239-2243 (1995).
Morsch,Monatsh Chem64:333-338 (1934).
Mousa et al.,Cardiovacular Res47(4):819-826 (2000).
Rodionow et al.,J Obsc Chim3:628-632 (1933).
Sebatine et al.,Am J Med109(3):224-237 (2000).
Shantare et al.,Chem Heterocycl Comps34(3):351-358 (1998).
Biediger Ronald J.
Chen Qi
Decker E. Radford
Holland George W.
Kassir Jamal M.
Andres Janet L
Encysive Pharmaceuticals Inc.
Gallis David E
Jones Day
LandOfFree
Carboxylic acid derivatives that inhibit the binding of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Carboxylic acid derivatives that inhibit the binding of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Carboxylic acid derivatives that inhibit the binding of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4202126